Ani Pharmaceuticals, Inc. (BPAX)

Trade BPAX now with
2/27/2019 8:31:52 AM ANI Pharma Q4 GAAP EPS $0.46; Adj EPS $1.32
12/7/2018 8:02:52 AM ANI Enters Separate, Privately Negotiated Agreements With Certain Holders Of 3.00% Convertible Senior Notes Due 2019
11/6/2018 8:31:31 AM ANI Pharmaceuticals Q3 GAAP Net Income $5.0 Mln Or $0.42/Shr
10/4/2018 8:32:23 AM ANI Announces Launch Of Candesartan Hydrochlorothiazide Tablets, An Authorized Generic Of Atacand HCT
8/7/2018 8:31:40 AM ANI Pharma Q2 Net Revenues Of $47.3 Mln, Increase Of 6% From Lastyear
6/27/2018 8:02:39 AM ANI Pharmaceuticals Launches Cholestyramine For Oral Suspension USP, 4g/dose, In Cans
6/5/2018 8:31:16 AM ANI Shareholders Elect Three Members To Board
5/8/2018 8:31:37 AM ANI Pharma Q1 GAAP EPS $0.19 Vs $0.10 Last Year
5/7/2018 8:31:23 AM ANI Pharmaceuticals Completes Acquisition Of Generic Products And Assets From Amneal/Impax
4/27/2018 7:32:44 PM ANI Pharmaceuticals Signs Definitive Agreements To Acquire Generic Products And Assets From Amneal/Impax
4/18/2018 8:32:52 AM ANI Gets FDA Approval For Its ANDA For Morphine Sulfate Oral Solution 10mg/5mL, 20mg/5mL And 100mg/5ml
4/4/2018 8:32:53 AM ANI Acquires ANDAs For 23 Previously Marketed Generic Drug Products From IDT Australia